TY - JOUR
TI - Generalized Lichen Planus-like Eruption Related to Trimebutine.
AU - Koumaki, Dimitra
AU - Koumaki, Vasiliki
AU - Katoulis, Alexander
AU - Boumpoucheropoulos, Sotirios
AU - Evangelou, George
AU - Stefanidou, Maria
AU - Krasagakis, Konstantinos
JO - European Journal of Case Reports in Internal Medicine
PY - 2020
VL - 7
TODO - 12
SP - 002103
PB - 
SN - null
TODO - 10.12890/2020_002103
TODO - lichen planus, cutaneous adverse reaction, lichenoid drug eruption, Trimebutine maleate
TODO - Trimebutine is a spasmolytic agent with antimuscarinic effects that is used for the treatment of irritable bowel syndrome (IBS) and lower gastrointestinal tract  motility disorders. Lichenoid drug eruptions (LDE) to trimebutine maleate have not  been previously reported. Here we present the case of a 50-year-old male patient who  developed an extensive lichenoid eruption on his upper and lower extremities and  trunk 4 weeks after starting treatment with trimebutine maleate 300 mg once daily  for IBS. Two months after discontinuation of the drug and administration of topical  treatment with emollients and corticosteroids, the LDE cleared completely with no  recurrence. The diagnosis of LDE due to trimebutine was made, based upon the  clinical features resembling lichen planus, the histological findings of interface  dermatitis, the evidence of a temporal relationship between drug intake and the  development of skin lesions, and resolution upon discontinuation of the drug. To the  best of the authors' knowledge, LDE following trimebutine maleate intake has not  been previously reported. Management of trimebutine-induced LDE includes withdrawal  of the causative agent and treatment with potent topical corticosteroids. LEARNING  POINTS: Cutaneous adverse events due to trimebutine maleate, an antispasmodic agent  frequently used for the treatment of irritable bowel syndrome (IBS), have rarely  been reported.Lichenoid drug eruption (LDE), also called drug-induced lichen planus,  is an uncommon cutaneous adverse effect of several drugs.Here we report the first  case of trimebutine maleate-induced LDE.
ER -